2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
02.17.17
Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
01.31.17
Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
01.19.17
Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology
01.05.17
Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
01.04.17
Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.